Paul Hockings, Senior Director MR Imaging, has been invited to give an Industry Perspective at the 8th Kidney Disease Clinical Trialists (KDCT) Workshop later this week. Paul will be a discussant in the ‘Shifting early development trials from the EGFR/UACR ratio paradigm to a multiplexed biomarker enabled strategy’ session on Friday, March 15. This year’s KDCT workshop is from March 15-16 in Washington D.C.
The KDCT Workshop is a specialised closed meeting for nephrologists, clinical trialists, principal investigators, and statisticians across academia, industry and regulatory/health bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The workshop aims to foster an exchange of ideas with the objective of improving kidney disease clinical trials.
Paul’s contribution will focus on how advanced imaging techniques like Magnetic Resonance Imaging (MRI) can provide additional information and insights in kidney disease clinical trials beyond what is possible with current biomarkers such as estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). It provides a way to assess renal structure, function, and unique insights on pathophysiology with high precision and good reproducibility. Kidney MRI biomarkers can add value particularly in early clinical trials to address specific clinical questions, build confidence, and minimise risk when moving forward to later stages of drug development.